The estimated Net Worth of Pharmaceuticals Inc Ionis is at least $1.79 Milliarde dollars as of 10 October 2020. Pharmaceuticals Ionis owns over 21,237,715 units of Akcea Therapeutics Inc stock worth over $1,786,517,953 and over the last 12 years Pharmaceuticals sold AKCA stock worth over $3,780,156.
Sign up
Pharmaceuticals Ionis AKCA stock SEC Form 4 insiders trading
Pharmaceuticals has made over 6 trades of the Akcea Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals bought 21,237,715 units of AKCA stock worth $385,464,527 on 10 October 2020.
The largest trade Pharmaceuticals's ever made was buying 21,237,715 units of Akcea Therapeutics Inc stock on 10 October 2020 worth over $385,464,527. On average, Pharmaceuticals trades about 3,613,576 units every 292 days since 2012. As of 10 October 2020 Pharmaceuticals still owns at least 98,322,397 units of Akcea Therapeutics Inc stock.
You can see the complete history of Pharmaceuticals Ionis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pharmaceuticals Ionis's mailing address?
Pharmaceuticals's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.
Insiders trading at Akcea Therapeutics Inc
Over the last 7 years, insiders at Akcea Therapeutics Inc have traded over $384,023 worth of Akcea Therapeutics Inc stock and bought 35,029,381 units worth $610,464,515 . The most active insiders traders include Pharmaceuticals Inc Ionis, Paula Soteropoulos und B Lynne Parshall. On average, Akcea Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $40,228,816. The most recent stock trade was executed by Pharmaceuticals Inc Ionis on 10 October 2020, trading 21,237,715 units of AKCA stock currently worth $385,464,527.
What does Akcea Therapeutics Inc's logo look like?
Complete history of Pharmaceuticals Ionis stock trades at Regulus Therapeutics Inc und Akcea Therapeutics Inc
Akcea Therapeutics Inc executives and stock owners
Akcea Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Barbara Yanni,
Director -
Amber Salzman,
Director -
Joseph Iii Klein,
Director -
Michael J. Yang,
Director -
Pharmaceuticals Inc Ionis,
10% owner -
Michael F Mac Lean,
Chief Financial Officer -
Jeff Marc Goldberg,
Chief Operating Officer -
Louis O'dea,
Chief Medical Officer -
Paula Soteropoulos,
Chief Executive Officer -
Elaine Hochberg,
Director -
Edward M Fitzgerald,
Director -
Sandford D Smith,
Director -
Richard A Moscicki,
Director -
Sarah Boyce,
President -
Christopher Gabrieli,
Director -
Alex G. Howarth,
Chief Operating Officer -
B Lynne Parshall,
Director -
Kyle Jenne,
Chief Commercial Officer -
Michael Dennis Price,
Chief Financial Officer -
Damien Mc Devitt,
Chief Executive Officer -
Joshua F. Patterson,
General Counsel -
William T. Andrews,
Chief Medical Officer